Chemed Corporation (CHE) Stock Competitors & Peer Comparison
See (CHE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CHE | $442.00 | +3.55% | 5.7B | 23.60 | $18.32 | +0.56% |
| HCA | $371.05 | +2.15% | 80.3B | 12.47 | $29.02 | +0.81% |
| SOLV | $81.09 | +3.48% | 14.3B | 10.09 | $8.17 | N/A |
| THC | $162.77 | -1.26% | 13.9B | 8.38 | $19.24 | N/A |
| DVA | $192.55 | -1.27% | 12.3B | 18.50 | $10.38 | N/A |
| FMS | $22.06 | +5.55% | 11.8B | 11.54 | $1.90 | +3.96% |
| EHC | $104.37 | +1.16% | 9.9B | 17.10 | $5.84 | +0.74% |
| ENSG | $170.45 | +2.26% | 9.6B | 26.71 | $6.15 | +0.16% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| UHS | $146.19 | +0.14% | 8.9B | 5.96 | $23.95 | +0.56% |
Stock Comparison
CHE vs HCA Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, HCA has a market cap of 80.3B. Regarding current trading prices, CHE is priced at $442.00, while HCA trades at $371.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas HCA's P/E ratio is 12.47. In terms of profitability, CHE's ROE is +0.25%, compared to HCA's ROE of -1.23%. Regarding short-term risk, CHE is more volatile compared to HCA. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check HCA's competition here
CHE vs SOLV Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, SOLV has a market cap of 14.3B. Regarding current trading prices, CHE is priced at $442.00, while SOLV trades at $81.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas SOLV's P/E ratio is 10.09. In terms of profitability, CHE's ROE is +0.25%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, CHE is more volatile compared to SOLV. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check SOLV's competition here
CHE vs THC Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, THC has a market cap of 13.9B. Regarding current trading prices, CHE is priced at $442.00, while THC trades at $162.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas THC's P/E ratio is 8.38. In terms of profitability, CHE's ROE is +0.25%, compared to THC's ROE of +0.41%. Regarding short-term risk, CHE is more volatile compared to THC. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check THC's competition here
CHE vs DVA Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, DVA has a market cap of 12.3B. Regarding current trading prices, CHE is priced at $442.00, while DVA trades at $192.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas DVA's P/E ratio is 18.50. In terms of profitability, CHE's ROE is +0.25%, compared to DVA's ROE of -1.33%. Regarding short-term risk, CHE is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check DVA's competition here
CHE vs FMS Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, FMS has a market cap of 11.8B. Regarding current trading prices, CHE is priced at $442.00, while FMS trades at $22.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas FMS's P/E ratio is 11.54. In terms of profitability, CHE's ROE is +0.25%, compared to FMS's ROE of +0.07%. Regarding short-term risk, CHE is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check FMS's competition here
CHE vs EHC Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, EHC has a market cap of 9.9B. Regarding current trading prices, CHE is priced at $442.00, while EHC trades at $104.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas EHC's P/E ratio is 17.10. In terms of profitability, CHE's ROE is +0.25%, compared to EHC's ROE of +0.25%. Regarding short-term risk, CHE is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check EHC's competition here
CHE vs ENSG Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, ENSG has a market cap of 9.6B. Regarding current trading prices, CHE is priced at $442.00, while ENSG trades at $170.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas ENSG's P/E ratio is 26.71. In terms of profitability, CHE's ROE is +0.25%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, CHE is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check ENSG's competition here
CHE vs OSH Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, CHE is priced at $442.00, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas OSH's P/E ratio is -17.65. In terms of profitability, CHE's ROE is +0.25%, compared to OSH's ROE of +4.64%. Regarding short-term risk, CHE is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check OSH's competition here
CHE vs UHS Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, UHS has a market cap of 8.9B. Regarding current trading prices, CHE is priced at $442.00, while UHS trades at $146.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas UHS's P/E ratio is 5.96. In terms of profitability, CHE's ROE is +0.25%, compared to UHS's ROE of +0.21%. Regarding short-term risk, CHE is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check UHS's competition here
CHE vs LHCG Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, CHE is priced at $442.00, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas LHCG's P/E ratio is 82.83. In terms of profitability, CHE's ROE is +0.25%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, CHE is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check LHCG's competition here
CHE vs MMED Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, MMED has a market cap of 3.9B. Regarding current trading prices, CHE is priced at $442.00, while MMED trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas MMED's P/E ratio is -11.07. In terms of profitability, CHE's ROE is +0.25%, compared to MMED's ROE of -0.09%. Regarding short-term risk, CHE is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check MMED's competition here
CHE vs AMED Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, CHE is priced at $442.00, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AMED's P/E ratio is 39.30. In terms of profitability, CHE's ROE is +0.25%, compared to AMED's ROE of +0.09%. Regarding short-term risk, CHE is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check AMED's competition here
CHE vs OPCH Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, OPCH has a market cap of 3.2B. Regarding current trading prices, CHE is priced at $442.00, while OPCH trades at $20.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas OPCH's P/E ratio is 15.68. In terms of profitability, CHE's ROE is +0.25%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, CHE is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check OPCH's competition here
CHE vs LFST Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, LFST has a market cap of 3B. Regarding current trading prices, CHE is priced at $442.00, while LFST trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas LFST's P/E ratio is 127.33. In terms of profitability, CHE's ROE is +0.25%, compared to LFST's ROE of +0.02%. Regarding short-term risk, CHE is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check LFST's competition here
CHE vs NHC Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, NHC has a market cap of 2.9B. Regarding current trading prices, CHE is priced at $442.00, while NHC trades at $193.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas NHC's P/E ratio is 23.80. In terms of profitability, CHE's ROE is +0.25%, compared to NHC's ROE of +0.12%. Regarding short-term risk, CHE is more volatile compared to NHC. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check NHC's competition here
CHE vs BKD Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, BKD has a market cap of 2.8B. Regarding current trading prices, CHE is priced at $442.00, while BKD trades at $12.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas BKD's P/E ratio is -13.67. In terms of profitability, CHE's ROE is +0.25%, compared to BKD's ROE of +401.19%. Regarding short-term risk, CHE is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check BKD's competition here
CHE vs ACHC Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, ACHC has a market cap of 2.3B. Regarding current trading prices, CHE is priced at $442.00, while ACHC trades at $24.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas ACHC's P/E ratio is -2.07. In terms of profitability, CHE's ROE is +0.25%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, CHE is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ACHC's competition here
CHE vs SEM Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, CHE is priced at $442.00, while SEM trades at $16.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas SEM's P/E ratio is 15.42. In terms of profitability, CHE's ROE is +0.25%, compared to SEM's ROE of +0.08%. Regarding short-term risk, CHE is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check SEM's competition here
CHE vs ASTH Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, ASTH has a market cap of 1.9B. Regarding current trading prices, CHE is priced at $442.00, while ASTH trades at $38.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas ASTH's P/E ratio is 62.05. In terms of profitability, CHE's ROE is +0.25%, compared to ASTH's ROE of +0.04%. Regarding short-term risk, CHE is more volatile compared to ASTH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check ASTH's competition here
CHE vs MD Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, MD has a market cap of 1.8B. Regarding current trading prices, CHE is priced at $442.00, while MD trades at $22.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas MD's P/E ratio is 10.86. In terms of profitability, CHE's ROE is +0.25%, compared to MD's ROE of +0.20%. Regarding short-term risk, CHE is more volatile compared to MD. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check MD's competition here
CHE vs AMEH Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, CHE is priced at $442.00, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AMEH's P/E ratio is 39.25. In terms of profitability, CHE's ROE is +0.25%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, CHE is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AMEH's competition here
CHE vs SGRY Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, SGRY has a market cap of 1.8B. Regarding current trading prices, CHE is priced at $442.00, while SGRY trades at $13.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas SGRY's P/E ratio is -23.19. In terms of profitability, CHE's ROE is +0.25%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, CHE is more volatile compared to SGRY. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check SGRY's competition here
CHE vs ADUS Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, ADUS has a market cap of 1.7B. Regarding current trading prices, CHE is priced at $442.00, while ADUS trades at $92.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas ADUS's P/E ratio is 16.55. In terms of profitability, CHE's ROE is +0.25%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, CHE is more volatile compared to ADUS. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check ADUS's competition here
CHE vs AGL Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AGL has a market cap of 1.6B. Regarding current trading prices, CHE is priced at $442.00, while AGL trades at $95.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AGL's P/E ratio is -4.22. In terms of profitability, CHE's ROE is +0.25%, compared to AGL's ROE of -1.46%. Regarding short-term risk, CHE is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AGL's competition here
CHE vs AVAH Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AVAH has a market cap of 1.4B. Regarding current trading prices, CHE is priced at $442.00, while AVAH trades at $6.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AVAH's P/E ratio is 5.48. In terms of profitability, CHE's ROE is +0.25%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, CHE is more volatile compared to AVAH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check AVAH's competition here
CHE vs HCSG Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, HCSG has a market cap of 1.4B. Regarding current trading prices, CHE is priced at $442.00, while HCSG trades at $20.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas HCSG's P/E ratio is 21.51. In terms of profitability, CHE's ROE is +0.25%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, CHE is more volatile compared to HCSG. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check HCSG's competition here
CHE vs CMPS Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, CMPS has a market cap of 1.3B. Regarding current trading prices, CHE is priced at $442.00, while CMPS trades at $11.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas CMPS's P/E ratio is -4.16. In terms of profitability, CHE's ROE is +0.25%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, CHE is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CMPS's competition here
CHE vs BKDT Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, CHE is priced at $442.00, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas BKDT's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, CHE is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check BKDT's competition here
CHE vs ARDT Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, ARDT has a market cap of 1.2B. Regarding current trading prices, CHE is priced at $442.00, while ARDT trades at $8.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas ARDT's P/E ratio is 9.14. In terms of profitability, CHE's ROE is +0.25%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, CHE is more volatile compared to ARDT. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check ARDT's competition here
CHE vs AMN Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AMN has a market cap of 1.2B. Regarding current trading prices, CHE is priced at $442.00, while AMN trades at $31.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AMN's P/E ratio is -35.59. In terms of profitability, CHE's ROE is +0.25%, compared to AMN's ROE of -0.05%. Regarding short-term risk, CHE is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AMN's competition here
CHE vs PNTG Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, PNTG has a market cap of 1B. Regarding current trading prices, CHE is priced at $442.00, while PNTG trades at $31.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas PNTG's P/E ratio is 35.02. In terms of profitability, CHE's ROE is +0.25%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, CHE is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check PNTG's competition here
CHE vs INNV Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, INNV has a market cap of 977.3M. Regarding current trading prices, CHE is priced at $442.00, while INNV trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas INNV's P/E ratio is -90.00. In terms of profitability, CHE's ROE is +0.25%, compared to INNV's ROE of -0.09%. Regarding short-term risk, CHE is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check INNV's competition here
CHE vs USPH Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, USPH has a market cap of 940.4M. Regarding current trading prices, CHE is priced at $442.00, while USPH trades at $63.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas USPH's P/E ratio is 123.58. In terms of profitability, CHE's ROE is +0.25%, compared to USPH's ROE of +0.00%. Regarding short-term risk, CHE is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check USPH's competition here
CHE vs TALK Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, TALK has a market cap of 871.1M. Regarding current trading prices, CHE is priced at $442.00, while TALK trades at $5.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas TALK's P/E ratio is 130.00. In terms of profitability, CHE's ROE is +0.25%, compared to TALK's ROE of +0.01%. Regarding short-term risk, CHE is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check TALK's competition here
CHE vs FSHCX Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, FSHCX has a market cap of 825.5M. Regarding current trading prices, CHE is priced at $442.00, while FSHCX trades at $108.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas FSHCX's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to FSHCX's ROE of N/A. Regarding short-term risk, CHE is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check FSHCX's competition here
CHE vs EHAB Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, CHE is priced at $442.00, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas EHAB's P/E ratio is -197.14. In terms of profitability, CHE's ROE is +0.25%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, CHE is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check EHAB's competition here
CHE vs SNDA Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, SNDA has a market cap of 663.2M. Regarding current trading prices, CHE is priced at $442.00, while SNDA trades at $34.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas SNDA's P/E ratio is -5.68. In terms of profitability, CHE's ROE is +0.25%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, CHE is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SNDA's competition here
CHE vs GMRS Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, GMRS has a market cap of 501M. Regarding current trading prices, CHE is priced at $442.00, while GMRS trades at $11.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas GMRS's P/E ratio is 5.69. In terms of profitability, CHE's ROE is +0.25%, compared to GMRS's ROE of N/A. Regarding short-term risk, CHE is less volatile compared to GMRS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check GMRS's competition here
CHE vs TOI Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, TOI has a market cap of 473.9M. Regarding current trading prices, CHE is priced at $442.00, while TOI trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas TOI's P/E ratio is -13.54. In terms of profitability, CHE's ROE is +0.25%, compared to TOI's ROE of +3.27%. Regarding short-term risk, CHE is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TOI's competition here
CHE vs MCTA Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, CHE is priced at $442.00, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas MCTA's P/E ratio is 419.36. In terms of profitability, CHE's ROE is +0.25%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, CHE is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check MCTA's competition here
CHE vs CCRN Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, CCRN has a market cap of 426.5M. Regarding current trading prices, CHE is priced at $442.00, while CCRN trades at $13.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas CCRN's P/E ratio is -4.32. In terms of profitability, CHE's ROE is +0.25%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, CHE is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check CCRN's competition here
CHE vs AIRS Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AIRS has a market cap of 402.8M. Regarding current trading prices, CHE is priced at $442.00, while AIRS trades at $5.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AIRS's P/E ratio is -33.59. In terms of profitability, CHE's ROE is +0.25%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, CHE is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AIRS's competition here
CHE vs CYH Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, CYH has a market cap of 392.5M. Regarding current trading prices, CHE is priced at $442.00, while CYH trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas CYH's P/E ratio is 0.81. In terms of profitability, CHE's ROE is +0.25%, compared to CYH's ROE of +0.06%. Regarding short-term risk, CHE is more volatile compared to CYH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check CYH's competition here
CHE vs AUNA Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AUNA has a market cap of 334.6M. Regarding current trading prices, CHE is priced at $442.00, while AUNA trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AUNA's P/E ratio is 16.74. In terms of profitability, CHE's ROE is +0.25%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, CHE is more volatile compared to AUNA. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check AUNA's competition here
CHE vs AONC Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AONC has a market cap of 292.5M. Regarding current trading prices, CHE is priced at $442.00, while AONC trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AONC's P/E ratio is -11.24. In terms of profitability, CHE's ROE is +0.25%, compared to AONC's ROE of +0.06%. Regarding short-term risk, CHE is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check AONC's competition here
CHE vs CSU Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, CHE is priced at $442.00, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas CSU's P/E ratio is 0.67. In terms of profitability, CHE's ROE is +0.25%, compared to CSU's ROE of -0.51%. Regarding short-term risk, CHE is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CSU's competition here
CHE vs JYNT Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, JYNT has a market cap of 117.3M. Regarding current trading prices, CHE is priced at $442.00, while JYNT trades at $8.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas JYNT's P/E ratio is 91.44. In terms of profitability, CHE's ROE is +0.25%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, CHE is more volatile compared to JYNT. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check JYNT's competition here
CHE vs NAKAW Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, CHE is priced at $442.00, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas NAKAW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, CHE is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check NAKAW's competition here
CHE vs BTMD Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, BTMD has a market cap of 104.1M. Regarding current trading prices, CHE is priced at $442.00, while BTMD trades at $2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas BTMD's P/E ratio is 5.49. In terms of profitability, CHE's ROE is +0.25%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, CHE is more volatile compared to BTMD. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check BTMD's competition here
CHE vs FVE Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, CHE is priced at $442.00, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas FVE's P/E ratio is -5.64. In terms of profitability, CHE's ROE is +0.25%, compared to FVE's ROE of -0.15%. Regarding short-term risk, CHE is more volatile compared to FVE. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check FVE's competition here
CHE vs KDLYW Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, CHE is priced at $442.00, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas KDLYW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, CHE is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check KDLYW's competition here
CHE vs DCGO Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, DCGO has a market cap of 56.3M. Regarding current trading prices, CHE is priced at $442.00, while DCGO trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas DCGO's P/E ratio is -0.30. In terms of profitability, CHE's ROE is +0.25%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, CHE is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check DCGO's competition here
CHE vs ALR Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, CHE is priced at $442.00, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas ALR's P/E ratio is -1.11. In terms of profitability, CHE's ROE is +0.25%, compared to ALR's ROE of -0.15%. Regarding short-term risk, CHE is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check ALR's competition here
CHE vs PIII Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, PIII has a market cap of 37.1M. Regarding current trading prices, CHE is priced at $442.00, while PIII trades at $11.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas PIII's P/E ratio is -0.29. In terms of profitability, CHE's ROE is +0.25%, compared to PIII's ROE of +1.85%. Regarding short-term risk, CHE is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check PIII's competition here
CHE vs IMAC Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, CHE is priced at $442.00, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas IMAC's P/E ratio is -2.27. In terms of profitability, CHE's ROE is +0.25%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, CHE is more volatile compared to IMAC. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check IMAC's competition here
CHE vs CCEL Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, CCEL has a market cap of 28.2M. Regarding current trading prices, CHE is priced at $442.00, while CCEL trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas CCEL's P/E ratio is -10.94. In terms of profitability, CHE's ROE is +0.25%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, CHE is more volatile compared to CCEL. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check CCEL's competition here
CHE vs CANO-WT Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, CHE is priced at $442.00, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, CHE is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CANO-WT's competition here
CHE vs AIH Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, CHE is priced at $442.00, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AIH's P/E ratio is -2.78. In terms of profitability, CHE's ROE is +0.25%, compared to AIH's ROE of +1.16%. Regarding short-term risk, CHE is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AIH's competition here
CHE vs CANO Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, CHE is priced at $442.00, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas CANO's P/E ratio is -0.01. In terms of profitability, CHE's ROE is +0.25%, compared to CANO's ROE of -1.49%. Regarding short-term risk, CHE is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CANO's competition here
CHE vs FTRP Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, CHE is priced at $442.00, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas FTRP's P/E ratio is -1.22. In terms of profitability, CHE's ROE is +0.25%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, CHE is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check FTRP's competition here
CHE vs AMS Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AMS has a market cap of 9.2M. Regarding current trading prices, CHE is priced at $442.00, while AMS trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AMS's P/E ratio is -6.32. In terms of profitability, CHE's ROE is +0.25%, compared to AMS's ROE of -0.06%. Regarding short-term risk, CHE is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AMS's competition here
CHE vs MODV Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, CHE is priced at $442.00, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas MODV's P/E ratio is -0.03. In terms of profitability, CHE's ROE is +0.25%, compared to MODV's ROE of +1.84%. Regarding short-term risk, CHE is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check MODV's competition here
CHE vs SYRA Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, SYRA has a market cap of 5.8M. Regarding current trading prices, CHE is priced at $442.00, while SYRA trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas SYRA's P/E ratio is -25.50. In terms of profitability, CHE's ROE is +0.25%, compared to SYRA's ROE of -0.08%. Regarding short-term risk, CHE is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SYRA's competition here
CHE vs GBNH Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, CHE is priced at $442.00, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas GBNH's P/E ratio is -0.06. In terms of profitability, CHE's ROE is +0.25%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, CHE is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check GBNH's competition here
CHE vs RHE Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, CHE is priced at $442.00, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas RHE's P/E ratio is -1.79. In terms of profitability, CHE's ROE is +0.25%, compared to RHE's ROE of -0.36%. Regarding short-term risk, CHE is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check RHE's competition here
CHE vs RHE-PA Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, CHE is priced at $442.00, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, CHE's ROE is +0.25%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, CHE is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check RHE-PA's competition here
CHE vs TOIIW Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, TOIIW has a market cap of 4.9M. Regarding current trading prices, CHE is priced at $442.00, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas TOIIW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, CHE is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TOIIW's competition here
CHE vs ATIP Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, CHE is priced at $442.00, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas ATIP's P/E ratio is -0.03. In terms of profitability, CHE's ROE is +0.25%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, CHE is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ATIP's competition here
CHE vs IMACW Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, CHE is priced at $442.00, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas IMACW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, CHE is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check IMACW's competition here
CHE vs CCM Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, CCM has a market cap of 708.4K. Regarding current trading prices, CHE is priced at $442.00, while CCM trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas CCM's P/E ratio is -1.54. In terms of profitability, CHE's ROE is +0.25%, compared to CCM's ROE of +0.07%. Regarding short-term risk, CHE is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CCM's competition here
CHE vs MNDR Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, MNDR has a market cap of 637.7K. Regarding current trading prices, CHE is priced at $442.00, while MNDR trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas MNDR's P/E ratio is -0.30. In terms of profitability, CHE's ROE is +0.25%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, CHE is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check MNDR's competition here
CHE vs TALKW Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, TALKW has a market cap of 519.3K. Regarding current trading prices, CHE is priced at $442.00, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas TALKW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, CHE is more volatile compared to TALKW. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check TALKW's competition here
CHE vs NVOS Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, NVOS has a market cap of 394.6K. Regarding current trading prices, CHE is priced at $442.00, while NVOS trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas NVOS's P/E ratio is -0.02. In terms of profitability, CHE's ROE is +0.25%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, CHE is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check NVOS's competition here
CHE vs NIVF Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, NIVF has a market cap of 380.9K. Regarding current trading prices, CHE is priced at $442.00, while NIVF trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas NIVF's P/E ratio is 0.02. In terms of profitability, CHE's ROE is +0.25%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, CHE is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check NIVF's competition here
CHE vs BACK Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, BACK has a market cap of 172.9K. Regarding current trading prices, CHE is priced at $442.00, while BACK trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas BACK's P/E ratio is -0.02. In terms of profitability, CHE's ROE is +0.25%, compared to BACK's ROE of +1.05%. Regarding short-term risk, CHE is less volatile compared to BACK. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check BACK's competition here
CHE vs PIIIW Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, PIIIW has a market cap of 57.5K. Regarding current trading prices, CHE is priced at $442.00, while PIIIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, CHE's ROE is +0.25%, compared to PIIIW's ROE of +1.85%. Regarding short-term risk, CHE is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check PIIIW's competition here
CHE vs NIVFW Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, NIVFW has a market cap of 44.6K. Regarding current trading prices, CHE is priced at $442.00, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas NIVFW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, CHE is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check NIVFW's competition here
CHE vs IONM Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, IONM has a market cap of 313. Regarding current trading prices, CHE is priced at $442.00, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas IONM's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to IONM's ROE of +5.28%. Regarding short-term risk, CHE is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check IONM's competition here
CHE vs TLMDW Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas TLMDW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, CHE is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TLMDW's competition here
CHE vs AFAM Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas AFAM's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, CHE is less volatile compared to AFAM. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AFAM's competition here
CHE vs SLHGP Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, CHE's ROE is +0.25%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, CHE is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check SLHGP's competition here
CHE vs TLMD Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas TLMD's P/E ratio is -1.60. In terms of profitability, CHE's ROE is +0.25%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, CHE is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check TLMD's competition here
CHE vs NFH Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, NFH has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas NFH's P/E ratio is -19.75. In terms of profitability, CHE's ROE is +0.25%, compared to NFH's ROE of -0.06%. Regarding short-term risk, CHE is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check NFH's competition here
CHE vs ATIP-WT Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, CHE is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ATIP-WT's competition here
CHE vs DCGOW Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas DCGOW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, CHE is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check DCGOW's competition here
CHE vs KND Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, KND has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas KND's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.25%, compared to KND's ROE of -0.53%. Regarding short-term risk, CHE is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check KND's competition here
CHE vs TVTY Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas TVTY's P/E ratio is 19.06. In terms of profitability, CHE's ROE is +0.25%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, CHE is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check TVTY's competition here
CHE vs HNGR Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas HNGR's P/E ratio is 19.71. In terms of profitability, CHE's ROE is +0.25%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, CHE is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check HNGR's competition here
CHE vs SLHG Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas SLHG's P/E ratio is -1.48. In terms of profitability, CHE's ROE is +0.25%, compared to SLHG's ROE of N/A. Regarding short-term risk, CHE is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SLHG's competition here
CHE vs DVCR Comparison June 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.7B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, CHE is priced at $442.00, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 23.60, whereas DVCR's P/E ratio is 28.34. In terms of profitability, CHE's ROE is +0.25%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, CHE is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check DVCR's competition here